---
title: "Bayesian latent class analysis of pediatric tuberculosis diagnostics in Kenya"
id: "medrxiv-10-using-bayesian-latent-class-models-to-evaluate-tuberculosis-diagnostics-in-a"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-using-bayesian-latent-class-models-to-evaluate-tuberculosis-diagnostics-in-a"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1?rss=1"
published_at: "2026-11-19T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Bayesian latent class analysis of pediatric tuberculosis diagnostics in Kenya
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-using-bayesian-latent-class-models-to-evaluate-tuberculosis-diagnostics-in-a
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1?rss=1)
- **Published At:** 2026-11-19T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study applied three **Bayesian latent class models (BLCMs)** to estimate tuberculosis prevalence and diagnostic test accuracy without relying on a gold standard. - Investigators analyzed data from 452 symptomatic children aged ≤15 years in Nairobi who underwent chest x-ray, respiratory testing (Xpert Ultra, smear, culture), tuberculin skin test (TST), and interferon gamma release assay (IGRA). - Model 1 assumed conditional independence among tests; Model 2 added random effects to model shared biological or immunologic test dependence; Model 3 further adjusted for clinical covariates and NIH TB signs and symptoms. - Prevalence estimates varied by model: Model 1 ~20.2% (15.9–24.7), Model 2 ~24.5% (19.6–30.0), and Model 3 ~14.8% (11.0–19.3). All model-based prevalences exceeded the 9.9% identified by microbiological testing alone. - Under Model 3 (preferred by the authors), **culture** sensitivity was estimated at 56.9% and **GeneXpert MTB/RIF Ultra** sensitivity at 63.2%; **smear microscopy** sensitivity was lower at 29.8%. - **Chest radiography (CXR)** showed moderate sensitivity (79.7%) but limited specificity (40.2%), limiting its diagnostic rule-in value. - **IGRA** sensitivity and specificity were estimated at 63.7% and 81.5% respectively; **TST** sensitivity 50.1% and specificity 65.8% under Model 3. - Older age was associated with higher odds of TB (log-odds ratio 1.09; 95% CrI 0.14–2.18) in adjusted models. - Authors reported that sensitivity analyses indicated robustness to prior choices. The preprint status and restricted data access were noted as study constraints.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=JQpH1ijkAM5bwZEDDV0kxm457_6sXx_le3lRgWx7uiU-1795158970.7431006-1.2.1.1-Nj9UveiVyUBfmUETUu3CM9UstQ4ztxEAXbG83czEUg9ZHwlr8L00WUBJDMYhuPUm) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Using Bayesian latent class models to evaluate tuberculosis diagnostics in a pediatric cohort study in Kenya. [ View ORCID Profile](http://orcid.org/0009-0008-6446-0395)Jerphason Ongayo Mecha, George Odweso Muhua, Joy Githua, [ View ORCID Profile](http://orcid.org/0000-0002-3513-774X)Jaclyn N. Escudero, Lucy Kijaro, Lilian N. Njagi, Grace John-Stewart, Elizabeth Maleche-Obimbo, Videlis Nduba, Sylvia M. LaCourse, Lurdes Y.T. Inoue doi: https://doi.org/10.64898/2026.11.17.26368380 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Jerphason Ongayo Mecha 1 Kenya Medical Research Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jerphason%2B%2BOngayo%2BMecha%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mecha%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJerphason%2B%2BOngayo%2BMecha%2B) * [ORCID record for Jerphason Ongayo Mecha](http://orcid.org/0009-0008-6446-0395 "Open in new tab") * For correspondence: mechaongayo@gmail.com George Odweso Muhua 2 University of Nairobi; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=George%2B%2BOdweso%2BMuhua%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Muhua%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGeorge%2B%2BOdweso%2BMuhua%2B) Joy Githua 1 Kenya Medical Research Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joy%2BGithua%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Githua%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoy%2BGithua%2B) Jaclyn N. Escudero 3 University of Washington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jaclyn%2BN.%2BEscudero%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=N.%20Escudero%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJaclyn%2BN.%2BEscudero%2B) * [ORCID record for Jaclyn N. Escudero](http://orcid.org/0000-0002-3513-774X "Open in new tab") Lucy Kijaro 1 Kenya Medical Research Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lucy%2BKijaro%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kijaro%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALucy%2BKijaro%2B) Lilian N. Njagi 1 Kenya Medical Research Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lilian%2BN.%2BNjagi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=N.%20Njagi%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALilian%2BN.%2BNjagi%2B) Grace John-Stewart 3 University of Washington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Grace%2BJohn-Stewart%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=John-Stewart%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGrace%2BJohn-Stewart%2B) Elizabeth Maleche-Obimbo 4 University of Nairobi Faculty of Health Sciences * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elizabeth%2BMaleche-Obimbo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Maleche-Obimbo%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElizabeth%2BMaleche-Obimbo%2B) Videlis Nduba 1 Kenya Medical Research Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Videlis%2BNduba%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nduba%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVidelis%2BNduba%2B) Sylvia M. LaCourse 3 University of Washington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sylvia%2BM.%2BLaCourse%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=M.%20LaCourse%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASylvia%2BM.%2BLaCourse%2B) Lurdes Y.T. Inoue 3 University of Washington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lurdes%2BY.T.%2BInoue%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Y.T.%20Inoue%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALurdes%2BY.T.%2BInoue%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1349296/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1349296/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1349296/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1349296/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1349296/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Pediatric tuberculosis (TB) remains difficult to diagnose. Culture, the gold standard, has limited sensitivity in children (~40-60%). We analyzed 452 symptomatic children ≤15 years who underwent chest x-ray (CXR), respiratory sample testing with Xpert Ultra, smear microscopy and culture, tuberculin skin test (TST), and interferon gamma release assay (IGRA) in Nairobi, Kenya. Methods: Three Bayesian latent class models (BLCMs) were used: Model 1 assumed conditional test independence; Model 2 incorporated random effects to account for shared biological (Smear, geneXpert Ultra/RIF and culture) or immunologic (IGRA, TST) test dependence; Model 3 extended Model 2 by adjusting for clinical covariates and NIH TB signs and symptoms. We estimated TB prevalence, test sensitivities/specificities and covariate effects. Results: Prevalence estimates under Models 1 [20.2% (15.9–24.7)] and 2 [24.5% (19.6–30.0)] were higher than under Model 3 [14.8% (11.0–19.3)]. All the three model-based prevalence estimates were considerably higher than the 9.9% of children identified through microbiological testing alone. Sensitivity and specificity were broadly consistent across models. Model 3 was considered preferred because it accounted for dependence among the tests and adjusted prevalence and sensitivity for clinical covariates. Under this Model 3, culture and GeneXpert MTB/RIF Ultra demonstrated moderate sensitivity (56.9% and 63.2%, respectively), while smear microscopy showed lower sensitivity (29.8%). CXR achieved moderate sensitivity (79.7%) but limited specificity (40.2%). IGRA and TST displayed sensitivities of 63.7% and 50.1%, and specificities of 81.5% and 65.8%. Older age was positively associated with TB (log-odds ratio 1.09; 95% CrI: 0.14–2.18). Conclusion: BLCMs estimated TB prevalence and test accuracies without a gold standard. Sensitivity analyses confirmed robustness to priors. Radiography demonstrated moderate sensitivity while culture and GeneXpert retained excellent specificity with improved test performance with older age. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: University of Nairobi and Kenyatta National Hospital and the Scientific Ethics and Review Unit at Kenya Medical Research Institute I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data underlying this study contain sensitive patient information (including pediatric HIV status) and are subject to ethical restrictions imposed by the University of Nairobi and Kenyatta National Hospital and the Scientific Ethics and Review Unit at Kenya Medical Research Institute. Data cannot be shared publicly. De-identified data are available upon reasonable request to Sylvia M. LaCourse (sylvial2{at}uw.edu) for researchers who meet the criteria for access to confidential data. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.18.26368388v1 "Fine-tuned encoders, generative large language models and typed decisions for classifying findings in chest CT reports: paired English-Japanese internal testing and external testing on naturally written Japanese reports")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1 "Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk") Posted November 19, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/19/2026.11.17.26368380.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.17.26368380v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/19/2026.11.17.26368380.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Using Bayesian latent class models to evaluate tuberculosis diagnostics in a pediatric cohort study in Kenya. Jerphason Ongayo Mecha, George Odweso Muhua, Joy Githua, Jaclyn N. Escudero, Lucy Kijaro, Lilian N. Njagi, Grace John-Stewart, Elizabeth Maleche-Obimbo, Videlis Nduba, Sylvia M. LaCourse, Lurdes Y.T. Inoue medRxiv 2026.11.17.26368380; doi: https://doi.org/10.64898/2026.11.17.26368380 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368380v1%26text%3DUsing%2520Bayesian%2520latent%2520class%2520models%2520to%2520evaluate%2520tuberculosis%2520diagnostics%2520in%2520a%2520pediatric%2520cohort%2520study%2520in%2520Kenya. "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368380v1%26t%3DUsing%2520Bayesian%2520latent%2520class%2520models%2520to%2520evaluate%2520tuberculosis%2520diagnostics%2520in%2520a%2520pediatric%2520cohort%2520study%2520in%2520Kenya. "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368380v1%26title%3DUsing%2520Bayesian%2520latent%2520class%2520models%2520to%2520evaluate%2520tuberculosis%2520diagnostics%2520in%2520a%2520pediatric%2520cohort%2520study%2520in%2520Kenya.%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368380v1%26title%3DUsing%2520Bayesian%2520latent%2520class%2520models%2520to%2520evaluate%2520tuberculosis%2520diagnostics%2520in%2520a%2520pediatric%2520cohort%2520study%2520in%2520Kenya. "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.17.26368380) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.17.26368380v1&count=horizontal&via=&text=Using%20Bayesian%20latent%20class%20models%20to%20evaluate%20tuberculosis%20diagnostics%20in%20a%20pediatric%20cohort%20study%20in%20Kenya.&counturl=www.medrxiv.org/content/10.64898/2026.11.17.26368380v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (642) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (927) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (355) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5055) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (432) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (681) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1703) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16339) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (37) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1248) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7328) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (759) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1101) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5346) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1480) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1847) * [Hematology](https://www.medrxiv.org/collection/hematology) (604) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1389) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16534) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1209) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (702) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.me
## Related Clinical Research

- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [AI-guided nanoparticle therapeutics for infectious diseases integrating CRISPR, phage hybrids, and](https://medichelpline.com/clinical-feed/pubmed-43037917.md) (DOI: 10.1186/s11671-026-05108-1)
- [Viral suppression after test-and-treat in Ethiopia: rates and predictors in Shashemene cohort](https://medichelpline.com/clinical-feed/plos-one-21-viral-suppression-among-adolescents-and-adults-living-with-human.md)
- [Helicobacter pylori Serology and Resistant Hypertension: South African Cohort Protocol](https://medichelpline.com/clinical-feed/plos-one-20-protocol-for-investigating-the-association-between-helicobacter-pylori-exposure.md)
- [AI detection of pulmonary tuberculosis on chest X‑ray: meta-analysis of clinical cohort accuracy](https://medichelpline.com/clinical-feed/medrxiv-12-artificial-intelligence-for-pulmonary-tuberculosis-detection-on-chest-x-ray.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.